Bettina Brackertz

Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex

Sonja Stahl, Sabine Gaetzner, Bettina Brackertz et al. · Human Mutation · 2008 · 112 citations

Life Sciences, Molecular Genetics, Neurology +17

PD‐1 expression on Melan‐A‐reactive T cells increases during progression to metastatic disease

Holger Krönig, Kathrin Julia Falchner, Marcus Odendahl et al. · International Journal of Cancer · 2011 · 52 citations · Full text

Medicine, Immunology, Oncology +17

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6

Mathias Witzens‐Harig, Dirk Hose, Simone Jünger et al. · Blood · 2013 · 47 citations

Life Sciences, Immunology, Oncology +17

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes

Bettina Brackertz, Heinke Conrad, J. Daniel et al. · Blood Cancer Journal · 2011 · 13 citations · Full text

Life Sciences, Immunology, Oncology +11

First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.

David Belada, Kateřina Kopečková, Juan Bergua et al. · Journal of Clinical Oncology · 2021 · 12 citations

Medicine, Hematology, Oncology +14